Back to Search Start Over

Safety of Rotavirus Vaccination in Preterm Infants Admitted in Neonatal Intensive Care Units in Sicily, Italy: A Multicenter Observational Study

Authors :
Claudio Costantino
Arianna Conforto
Nicole Bonaccorso
Livia Cimino
Martina Sciortino
Mario Palermo
Kim Maiolo
Lucia Gabriella Tina
Pasqua Maria Betta
Mariacarmela Caracciolo
Carmine Mattia Loretta
Alessandro Arco
Eloisa Gitto
Salvino Marcello Vitaliti
Domenica Mancuso
Giuliana Vitaliti
Vincenzo Rosella
Giuseppa Pinello
Giovanni Corsello
Gregorio Serra
Bruna Gabriele
Fabio Tramuto
Vincenzo Restivo
Emanuele Amodio
Francesco Vitale
Costantino, Claudio
Conforto, Arianna
Bonaccorso, Nicole
Cimino, Livia
Sciortino, Martina
Palermo, Mario
Maiolo, Kim
Tina, Lucia Gabriella
Betta, Pasqua Maria
Caracciolo, Mariacarmela
Loretta, Carmine Mattia
Arco, Alessandro
Gitto, Eloisa
Vitaliti, Salvino Marcello
Mancuso, Domenica
Vitaliti, Giuliana
Rosella, Vincenzo
Pinello, Giuseppa
Corsello, Giovanni
Serra, Gregorio
Gabriele, Bruna
Tramuto, Fabio
Restivo, Vincenzo
Amodio, Emanuele
Vitale, Francesco
Source :
Vaccines; Volume 11; Issue 4; Pages: 718
Publication Year :
2023
Publisher :
Multidisciplinary Digital Publishing Institute, 2023.

Abstract

Rotavirus (RV) is among the most common vaccine-preventable diseases in children under five years of age. Despite the severity of rotavirus pathology in early childhood, rotavirus vaccination for children admitted to the neonatal intensive care unit (NICU), who are often born preterm and with various previous illnesses, is not performed. This multicenter, 3-year project aims to evaluate the safety of RV vaccine administration within the six main neonatal intensive care units of the Sicilian Region to preterm infants. Methods: Monovalent live attenuated anti-RV vaccination (RV1) was administered from April 2018 to December 2019 to preterm infants with gestational age ≥ 28 weeks. Vaccine administrations were performed in both inpatient and outpatient hospital settings as a post-discharge follow-up (NICU setting) starting at 6 weeks of age according to the official immunization schedule. Any adverse events (expected, unexpected, and serious) were monitored from vaccine administration up to 14 days (first assessment) and 28 days (second assessment) after each of the two scheduled vaccine doses. Results: At the end of December 2019, 449 preterm infants were vaccinated with both doses of rotavirus vaccine within the six participating Sicilian NICUs. Mean gestational age in weeks was 33.1 (±3.8 SD) and the first dose of RV vaccine was administered at 55 days (±12.9 SD) on average. The mean weight at the first dose was 3388 (SD ± 903) grams. Only 0.6% and 0.2% of infants reported abdominal colic and fever above 38.5 °C in the 14 days after the first dose, respectively. Overall, 1.9% EAEs were observed at 14 days and 0.4% at 28 days after the first/second dose administration. Conclusions: Data obtained from this study confirm the safety of the monovalent rotavirus vaccine even in preterm infants with gestational age ≥ 28 weeks, presenting an opportunity to improve the vaccination offer both in Sicily and in Italy by protecting the most fragile infants who are more at risk of contracting severe rotavirus gastroenteritis and nosocomial RV infection.

Details

Language :
English
ISSN :
2076393X
Database :
OpenAIRE
Journal :
Vaccines; Volume 11; Issue 4; Pages: 718
Accession number :
edsair.doi.dedup.....ed48ec5b9191a686c655c76ef1767c92
Full Text :
https://doi.org/10.3390/vaccines11040718